Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide orodispersible tablets once daily vs twice daily in eosinophilic esophagitis
2024-515229-26-00Phase 3Authorised
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of budesonide in eosinophilic esophagitis (EoE) (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Histological remission. Planned start May 2021; status: authorised.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2024-515229-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515229-26-00.